CASI Pharmaceuticals (FRA:ENM) Interest Expense: €-0.73 Mil (TTM As of Dec. 2025)

What is CASI Pharmaceuticals Interest Expense?

CASI Pharmaceuticals FRA:ENM 29 Interest Expense is €-0.73 Mil as of Dec. 2025. GuruFocus rates FRA:ENM with a GF Score™ of 29/100 and a GF Value™ of €11.74. The stock has 5 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. CASI Pharmaceuticals's interest expense for the three months ended in Dec. 2025 was € -0.17 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.73 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. CASI Pharmaceuticals's Operating Income for the three months ended in Dec. 2025 was € -9.95 Mil. CASI Pharmaceuticals's Interest Expense for the three months ended in Dec. 2025 was € -0.17 Mil. CASI Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

CASI Pharmaceuticals (FRA:ENM) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

CASI Pharmaceuticals's Interest Expense for the three months ended in Dec. 2025 was €-0.17 Mil. Its Operating Income for the three months ended in Dec. 2025 was €-9.95 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2025 was €1.23 Mil.

CASI Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

CASI Pharmaceuticals did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

CASI Pharmaceuticals Interest Expense Historical Data

* Premium members only.

The historical data trend for CASI Pharmaceuticals's Interest Expense can be seen below:

CASI Pharmaceuticals Interest Expense Chart

CASI Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Interest Expense

Get a 7-Day Free Trial

0.00

-0.06

-0.01

-0.83

-0.72

CASI Pharmaceuticals Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
Interest Expense	Get a 7-Day Free Trial															-0.27	-0.18	-0.21	-0.17	-0.17

29GF Score

CASI Pharmaceuticals Inc FRA:ENM

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

CASI Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.73 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of €-0.73 Mil mean?

CASI Pharmaceuticals (FRA:ENM) has a Interest Expense of €-0.73 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on CASI Pharmaceuticals and its competitors.

Is CASI Pharmaceuticals' Interest Expense too high?

CASI Pharmaceuticals' current Interest Expense is €-0.73 Mil. Overall, CASI Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.

How does CASI Pharmaceuticals' Interest Expense compare to ITRMF and OGEN?

CASI Pharmaceuticals' Interest Expense of €-0.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Biotechnology company?

A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on CASI Pharmaceuticals and its competitors. CASI Pharmaceuticals's current Interest Expense is €-0.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is CASI Pharmaceuticals stock overvalued right now?

CASI Pharmaceuticals (FRA:ENM) has a current Interest Expense of €-0.73 Mil. The stock's GF Value™ is €11.74, compared to a current price of €1.54 — trading 86.9% below its estimated fair value. The current Interest Expense is €-0.73 Mil. CASI Pharmaceuticals' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For CASI Pharmaceuticals (FRA:ENM), the current Interest Expense is €-0.73 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CASI Pharmaceuticals (FRA:ENM) Overvalued in 2026?

Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued. The current stock price of €1.54 is trading 86.9% below its estimated GF Value™ of €11.74.

Key valuation signals for FRA:ENM:

Interest Expense: €-0.73 Mil
GF Value™: €11.74 vs. price of €1.54 (86.9% below fair value)
GF Score™: 29/100 with 5 warning signs

No single metric tells the full story. See the FRA:ENM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CASI Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies ITRMF OGEN AZTR VRAX BBLG SLXN VIVS PKTX CDT CLDI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges CASIF:USA

Address Jianguo Road, No. 81, Room 1701-1702, China Central Office Tower 1, Huamao Office Building, Chaoyang District, Beijing, CHN, 100025

Website https://www.casipharmaceuticals.com

CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.

29GF Score

Get the complete analysis for FRA:ENM

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.54

Price

€11.74

GF Value

View FRA:ENM Analysis

See Interest Expense data for all stocks →